The patritumab-related AEs reported in ≥2 patients were ALT increased (n = 3), thrombocytopenia (n = 2), diarrhea (n = 2), stomatitis (n = 2), cheilitis (n = 2), rash maculo-papular (n = 2) and AST increased (n = 2) (Table 2). Here, GPT is linked to Thrombocytopenia.